Roxicodone Is the Answer!
Recently, Mallinckrodt, the Pharmaceuticals business of Covidien plc (COV), revealed that it has inked an agreement with Xanodyne Pharmaceuticals, an integrated specialty pharmaceutical company with expertise in pain management.
Per the agreement, Mallinckrodt bought Xanodyne’s Roxicodone’s (oxycodone hydrochloride tablets USP) in 5, 15 and 30 mg dosage strengths and acquired all rights to the Roxicodone New Drug Application (:NDA). Roxicodone is approved for moderate to severe pain management and is used where the application of an opioid analgesic is necessary. The drug is currently available in the U.S. The companies did not provide any financial details.
The inclusion of Roxicodone has enhanced Mallinckrodt’s pain management product portfolio. Mallinckrodt is a leading manufacturer of bulk acetaminophen in the world and the largest supplier of opioid pain management drugs in the U.S. It also ranks in the top 10 of prescription-based pharmaceutical manufacturers in the U.S. Exalgo and Pennsaid are its front-line branded products, which are successfully contributing to the company’s sales.